公开(公告)号：US20060189632A1

公开(公告)日：2006-08-24

申请号：US10547080

申请日：2004-03-01

申请人： Kenichiro Kataoka ,  Naotaka Suzuki ,  Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Aiko Fujino ,  Yasuhiro Oue ,  Yuko Yamakoshi ,  Satoshi Sugiura ,  Robert Mitchell ,  James Simpson ,  John Harris ,  Joelle Le

发明人： Kenichiro Kataoka ,  Naotaka Suzuki ,  Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Aiko Fujino ,  Yasuhiro Oue ,  Yuko Yamakoshi ,  Satoshi Sugiura ,  Robert Mitchell ,  James Simpson ,  John Harris ,  Joelle Le

IPC分类号： A61K31/519 ,  C07D487/04

CPC分类号： C07D487/04

摘要： The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.

公开(公告)号：US07557110B2

公开(公告)日：2009-07-07

申请号：US10547080

申请日：2004-03-01

申请人： Kenichiro Kataoka ,  Naotaka Suzuki ,  Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Aiko Fujino ,  Yasuhiro Oue ,  Yuko Yamakoshi ,  Satoshi Sugiura ,  Robert Dale Mitchell ,  James Donald Simpson ,  John Clifford Harris ,  Joelle Le

发明人： Kenichiro Kataoka ,  Naotaka Suzuki ,  Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Aiko Fujino ,  Yasuhiro Oue ,  Yuko Yamakoshi ,  Satoshi Sugiura ,  Robert Dale Mitchell ,  James Donald Simpson ,  John Clifford Harris ,  Joelle Le

IPC分类号： C07D487/04 ,  A61K31/519

CPC分类号： C07D487/04

摘要： The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.

摘要翻译： 由式I表示的吡唑并[1,5-a]嘧啶衍生物及其药学上可接受的盐表现出优异的激酶抑制活性。 因此，包含化合物作为有效成分的药物预期可用作其中涉及激酶的蛋白激酶介导的病症的治疗或预防剂，例如炎性疾病，自身免疫疾病，破坏性骨病，癌症和/或肿瘤生长。